HSP90の阻害は,腫瘍性EGF受容体の分解を誘導し,非小細胞肺がんの細胞増殖を抑制する.
PubMedで要約を見る
まとめ
この要約は機械生成です。熱ショックタンパク質90 (HSP90) 阻害剤は,表皮成長因子 (EGF) 受容体変異を有する非小細胞肺がん (NSCLC) の治療に有望である. これらの阻害剤はEGF受容体を劣化させることで腫瘍の成長を効果的に抑制し,TKI耐性NSCLCに対する新しい戦略を提供します.
科学分野
- 腫瘍学
- 分子生物学
- 薬物の発見
背景
- 皮質成長因子 (EGF) 受容体変異を有する非小細胞肺がん (NSCLC) 患者では,チロシンキナーゼ阻害剤 (TKIs) の有効性は限られている.
- EGF受容体のT790M/C797Sのような突然変異によるTKIsに対する獲得抵抗は,新しい治療戦略を必要とします.
- EGF受容体-L858RはNSCLCにおける一般的な活性化変異である.
研究 の 目的
- 様々なEGF受容体変異を有するNSCLC細胞における熱ショックタンパク質90 (HSP90) 阻害剤の治療の可能性を調査する.
- HSP90阻害剤がEGF受容体のシグナル伝達と分解経路に影響を与える根本的なメカニズムを解明する.
- NSCLCにおけるTKI耐性を克服するための戦略として,HSP90阻害剤を評価する.
主な方法
- 細胞活性はMTTアッセイを用いて評価された.
- 細胞増殖を評価するためにコロニー形成とEDU染色測定法を使用した.
- EGF受容体発現とシグナル伝達経路の阻害を分析するために,ウェスタン・ブロットと免疫光測定法を使用した.
- EGF受容体分解のメカニズムは,エンドソーム-ライソームとプロテオソーム経路を含む調査されました.
主要な成果
- HSP90阻害剤は,野生型,L858R,L858R/ T790M,L858R/ T790M/ C797S EGF受容体の変異を有するNSCLC細胞の成長と増殖を著しく抑制しました.
- HSP90阻害剤は腫瘍性EGF受容体の発現を低下させ,下流の信号伝達経路を阻害した.
- HSP90阻害剤は,エンドソーム- リソームとプロテアソームの両方の経路で変異したEGF受容体の分解を促進し,アグレソーム形成につながった.
結論
- HSP90阻害剤は,TKI耐性を含むEGF受容体変異性NSCLCに対する強力な抗がん活性を示しています.
- このメカニズムは EGF受容体の分解を誘導し,治療に有望な可能性をもたらします.
- HSP90阻害剤は,EGF受容体TKIに対する耐性を獲得したNSCLC患者に対する潜在的な治療戦略です.
関連する概念動画
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...

